Skip to main content
Clinical Trials/NCT05396144
NCT05396144
Recruiting
Phase 4

Evaluation of Nitrous Oxide Use in GI Endoscopy Procedures: Potential for Optimizing Sedation and Minimizing Side-Effects During Recovery

Stanford University1 site in 1 country100 target enrollmentMay 1, 2024
InterventionsNitrous oxide

Overview

Phase
Phase 4
Intervention
Nitrous oxide
Conditions
Endoscopy
Sponsor
Stanford University
Enrollment
100
Locations
1
Primary Endpoint
Intravenous sedative drug
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Nitrous oxide (commonly known as 'laughing gas') is often used during dental and other outpatient procedures, because it is easy to administer, is short-acting and rapidly clears from the body following the procedure.

The investigators hypothesize that use of Nitrous oxide during GI endoscopy may enhance patient comfort during the procedure and speed-up post-procedure recovery, while minimizing the fatigue and mental fogginess some patients report the day after receiving standard sedative and narcotic drugs used routinely for the procedure.

The investigators are interested in determining if adding Nitrous Oxide to commonly used sedation drugs will decrease fatigue, mental fogginess, and nausea/vomiting, as well as determine when the patient felt fully recovered from the effects of all sedatives given for the procedure.

Registry
clinicaltrials.gov
Start Date
May 1, 2024
End Date
January 1, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Tim Angelotti

Associate Professor of Anesthesiology, Perioperative and Pain Medicine

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Non-pregnant patients age 18 and older
  • Patient's presenting for upper endoscopy or colonoscopy under endoscopist- directed nurse sedation.
  • Patient is willing and able to consent and comply with study procedures.

Exclusion Criteria

  • Potentially vulnerable subjects including, homeless people, pregnant females, employees and students.
  • Participation in another investigational study that may directly or indirectly affect the results of this study within 30 days prior to the initial visit
  • Allergy to the proposed anesthetic agents (e.g. nitrous oxide, midazolam, fentanyl, diphenhydramine)

Arms & Interventions

5% inhaled nitrous oxide

Patients will received 5% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.

Intervention: Nitrous oxide

50% inhaled nitrous oxide

Patients will received 50% nitrous oxide by face mask in addition to standard intravenous sedatives given at the discretion of the care provider.

Intervention: Nitrous oxide

Outcomes

Primary Outcomes

Intravenous sedative drug

Time Frame: Duration of the procedure (1-2 hours)

Tabulate the types and dosages of intravenous sedative drugs given

Nausea/vomiting

Time Frame: 24-36 hours

Duration of nausea/vomiting

Recovery time

Time Frame: Duration of the procedure (1-3hours)

Time spent in procedure room to recover

Patient comfort

Time Frame: Duration of the procedure (1-3hours)

Patient comfort rating intra-procedure using standardized scale

Fatigue

Time Frame: 24-36 hours

The duration of fatigue experienced, if any

Mental Fogginess post-procedure/sedation

Time Frame: 24-36 hours

Number of patients who experienced mental fogginess post-procedure/sedation

Return to baseline function

Time Frame: 24-36 hours

Number of hours post-procedure/sedation for patient to return to baseline function

Study Sites (1)

Loading locations...

Similar Trials